Y79 Xenograft Model Service for Retinoblastoma

The Y79 Xenograft Model Service for Retinoblastoma provides a robust, clinically relevant preclinical platform for evaluating novel therapeutic strategies against one of the most common intraocular malignancies in children. Alfa Cytology leverages this well-established model to deliver comprehensive preclinical research services, enabling pharmaceutical and biotech partners to advance retinoblastoma drug development programs with confidence and precision.

Overview of Y79 Xenograft Model for Retinoblastoma

Retinoblastoma is the most frequent intraocular tumor in children, arising from the retina and characterized by rapid proliferation, extensive areas of ischemic necrosis, and a propensity for metastatic spread. The Y79 cell line, established in 1974 from the tumor of a 2.5-year-old Caucasian female with a strong maternal history of retinoblastoma, represents the first and most extensively characterized human retinoblastoma cell line available. Y79 cells exhibit hypertriploidy with variable chromosome numbers, grow as non-adherent floating aggregates in suspension culture, and retain high tumorigenic potential even after decades of propagation. These cells express markers of neuroectodermal origin including synaptophysin, as well as photoreceptor lineage markers such as arrestin 3 and CRX, reflecting their derivation from undifferentiated retinal progenitor cells.

In xenograft settings, Y79 cells demonstrate an invasive and metastatic phenotype distinct from other retinoblastoma cell lines such as WERI-Rb1. When introduced into the intraocular environment of immunocompromised animals, Y79-derived tumors exhibit histological features closely resembling human invasive retinoblastoma, including rosette-like growth patterns, large hyperchromatic nuclei with multiple nucleoli, and areas of necrosis and calcification. The model has been validated across multiple species including athymic nude mice and newborn rats, with tumor cells showing capacity to invade the retina, subretinal space, choroid, optic nerve head, and anterior chamber, with progression into the subarachnoid space and focal brain invasion in advanced cases. This aggressive behavior makes the Y79 xenograft particularly valuable for preclinical assessment of therapies targeting metastatic and advanced-stage disease.

• Efficacy Testing: Evaluating the in vivo anti-tumor activity of novel compounds, small molecules, biologics, or combination therapies targeting retinoblastoma.
• Mechanistic Studies: Investigating the complex molecular pathways driving retinoblastoma progression and metastatic spread, and how treatments intersect with these pathways.
• Biomarker Discovery: Identifying and validating potential biomarkers for treatment response or resistance in a controlled in vivo environment.

Figure 1. SAM inhibited cell viability and proliferation of Y79 cells. (Liu, Mushi, et al., 2024)

Cell Line Information: Y79

The Y79 cell line serves as the cornerstone of this xenograft model system. It is the first and most extensively characterized human retinoblastoma cell line available, with a well-documented origin, genetic profile, and phenotypic properties. Its ability to retain invasive and metastatic potential after decades of propagation makes it unique among available retinoblastoma cell lines and essential for aggressive disease modeling.

Our Services

Alfa Cytology offers comprehensive Y79 Xenograft Model Services tailored to your preclinical research objectives. Our experienced scientific team manages the entire workflow from cell line authentication and quality control to in vivo model construction, therapeutic intervention, and endpoint analysis. With validated protocols, rigorous quality assurance, and flexible study designs, we provide reliable data packages to support your retinoblastoma drug development pipeline---from early-stage candidate screening through to IND-enabling studies.

Workflow of Y79 Xenograft Model Construction

The construction of the Y79 xenograft model follows a standardized, multi-step workflow designed to ensure reproducible tumor growth and reliable therapeutic outcomes. At Alfa Cytology, we adhere to an optimized, multi-step workflow to ensure maximum take rates and reproducible growth kinetics. The streamlined workflow involves:

1. Cell Culture and Expansion: Y79 cells are revived from authenticated cryopreserved stocks and expanded in suspension culture using RPMI-1640 medium supplemented with fetal bovine serum. Cells are maintained under optimal growth conditions and monitored for viability, morphology, and mycoplasma contamination.
2. Cell Preparation for Injection: At the appropriate confluence, cells are harvested, counted, and resuspended at the desired concentration in sterile PBS or culture medium. Cell viability is confirmed by trypan blue exclusion, and cell suspensions are kept on ice until injection.
3. Animal Preparation and Anesthesia: Immunocompromised animals (athymic nude mice or NOD/SCID mice, typically 6-8 weeks old) are acclimatized and assessed for health status. Anesthesia is administered according to institutional animal care guidelines to ensure humane handling during the procedure.
4. Intraocular Injection: Y79 cell suspensions are injected into the intraocular space using a microsyringe. Common injection sites include the intravitreal space, anterior chamber, or subretinal space, depending on the study objectives. Injection volumes and cell numbers (typically 10^3 to 10^6 cells) are optimized for consistent tumor engraftment.
5. Tumor Monitoring and Growth Assessment: Animals are monitored regularly for tumor development using slit-lamp examination, fundoscopy, or bioluminescence imaging (for luciferase-expressing Y79-Luc cells). Tumor growth is documented through serial imaging, and tumor burden is quantified as photon flux or tumor volume measurements.
6. Endpoint Analysis and Sample Collection: At study termination, animals are euthanized according to humane endpoints. Eyes and relevant tissues are collected for histopathological analysis (H&E staining, immunohistochemistry), molecular profiling, and pharmacokinetic assessment. Tumor characteristics are compared against baseline parameters.

Figure 2: Schematic workflow illustrating the derivation and construction of the Y79 Xenograft Model at Alfa Cytology.

Case Study-Y79 Xenograft Model Development

Alfa Cytology has successfully established and validated the Y79 xenograft model across multiple preclinical studies. Our internal data demonstrate consistent tumor engraftment rates, reproducible growth kinetics, and predictable response patterns to standard-of-care chemotherapeutic agents including carboplatin, topotecan, and melphalan. Detailed tumor growth curves, survival data, histopathological analyses, and pharmacodynamic biomarker profiles are available upon request. For access to comprehensive study reports and customized data packages, please contact our scientific team directly.

Why Choose Alfa Cytology?

Alfa Cytology provides a comprehensive, quality-driven preclinical service platform built specifically for oncology drug development. Our Y79 Xenograft Model Service combines scientific expertise with operational excellence to deliver actionable data for your retinoblastoma research program.

• Verified Cell Line Integrity: Validated model systems with documented engraftment success rates and reproducible tumor growth kinetics.
• High Take Rates and Consistency: Full-service capability from cell line authentication and in vivo model construction through to endpoint analysis and data reporting.
• Comprehensive Analytical Support: Flexible study designs accommodating single-agent, combination, and dose-escalation protocols with customized endpoints.
• Tailored Study Designs: Experienced scientific team with deep expertise in pediatric ocular tumor models and retinoblastoma biology.
• Standardized Protocols: Rigorous quality control including mycoplasma testing, cell line authentication by STR profiling, and GLP-compliant documentation.
• Dedicated Project Management: Rapid project initiation with dedicated project management and regular progress updates throughout the study lifecycle.
• Competitive Timelines: Competitive timelines and transparent pricing structures tailored to biotech and pharmaceutical research budgets.

Contact Us

Ready to advance your retinoblastoma therapeutic program? Contact us today to discuss your project requirements, receive a detailed study proposal, or schedule a consultation with our preclinical oncology specialists. Please reach out to us today via our inquiry form or email to learn more about our Y79 Xenograft Model services.

For research use only. Not intended for any clinical use.